Bilateral uterine artery chemoembolization with methotrexate for cesarean scar pregnancy - 30/10/12
Reprints: Wei Huang, MD, Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Renminnanlu 3 duan 20hao, Chengdu, Sichuan 610041, People's Republic of ChinaRésumé |
Objective |
The objective of the study was to assess the efficacy of uterine arteries embolization (UAE) for the treatment of cesarean scar pregnancies (CSP).
Study Design |
Forty-six women with CSP were identified between March 2008 and March 2010. All of the patients underwent UAE combined with local methotrexate.
Results |
Forty-five patients were successfully treated. One patient had an emergency hysterectomy after 20 days because of massive vaginal hemorrhage. The mean time until normalization of serum β-human chorionic gonadotrophin was 37.7 days, and the mean time until CSP mass disappearance was 33.3 days. The mean hospitalization time was 10.5 days. The complications were mainly fever and pain, which were alleviated with symptomatic treatment. All 45 patients had recovered their normal menstruation at follow-up.
Conclusion |
Bilateral uterine artery chemoembolization with methotrexate appears to be a safe and effective treatment for CSP and causes less morbidity than current approaches.
Le texte complet de cet article est disponible en PDF.Key words : cesarean scar pregnancy, methotrexate, uterine artery chemoembolization
Plan
| The authors report no conflict of interest. |
|
| Cite this article as: Shen L, Tan A, Zhu H, et al. Bilateral uterine artery chemoembolization with methotrexate for cesarean scar pregnancy. Am J Obstet Gynecol 2012;207:386.e1-6. |
Vol 207 - N° 5
P. 386.e1-386.e6 - novembre 2012 Retour au numéro
Article précédent
- Cervical lidocaine for IUD insertional pain: a randomized controlled trial
- Colleen P. McNicholas, Tessa Madden, Qiuhong Zhao, Gina Secura, Jenifer E. Allsworth, Jeffrey F. Peipert
- Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial
- Ellen Mommers, Georges-Fabrice Blum, Thomas G. Gent, Klaus P. Peters, Terje S. Sørdal, Maya Marintcheva-Petrova
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?